🔧На сайте запланированы технические работы
25.12.2025 в промежутке с 18:00 до 21:00 по Московскому времени (GMT+3) на сайте будут проводиться плановые технические работы. Возможны перебои с доступом к сайту. Приносим извинения за временные неудобства. Благодарим за понимание!
🔧Site maintenance is scheduled.
Scheduled maintenance will be performed on the site from 6:00 PM to 9:00 PM Moscow time (GMT+3) on December 25, 2025. Site access may be interrupted. We apologize for the inconvenience. Thank you for your understanding!

 

Association between the Prevalence of Somatic Mutations in PIK3CA Gene in Tumors and Clinical and Morphological Characteristics of Breast Cancer Patients


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

The presence of activating somatic mutations in codons 542 and 545 of exon 9 (p.E542K c.1624G>A and p.E545K c.1633G>A) and in codon 1047 of exon 20 (p.H1047R c.3140A>G and p.H1047L c.3140A>T) of PIK3CA gene encoding catalytic p110α-subunit of phosphatidylinositol-3-kinase was studied in tumors of 473 breast cancer patients by multiplex allele-specific real-time PCR. Fifty-eight (12.3%) different mutations were found. An increase in the frequency of PIK3CA gene mutations with disease progression (from 2.4 to 28.7% with tumor progression from I-IIa to III-IV stage; p=0.0001) and a trend towards its increase in the tumors with unfavorable prognostic characteristics (high histological grade, triple negative phenotype) were demonstrated. The presence of the studied PIK3CA gene mutations in tumors significantly reduces relapse-free survival in the total group and in stage III cancer patients.

About the authors

M. L. Filipenko

Institute of Chemical Biology and Fundamental Medicine, Siberian Division of the Russian Academy of Sciences; Novosibirsk National Research State University

Author for correspondence.
Email: biochimia@yandex.ru
Russian Federation, Novosibirsk; Novosibirsk

N. A. Os’kina

Institute of Chemical Biology and Fundamental Medicine, Siberian Division of the Russian Academy of Sciences

Email: biochimia@yandex.ru
Russian Federation, Novosibirsk

I. A. Oskorbin

Institute of Chemical Biology and Fundamental Medicine, Siberian Division of the Russian Academy of Sciences; Novosibirsk National Research State University

Email: biochimia@yandex.ru
Russian Federation, Novosibirsk; Novosibirsk

O. V. Mishukova

Institute of Chemical Biology and Fundamental Medicine, Siberian Division of the Russian Academy of Sciences; Novosibirsk National Research State University

Email: biochimia@yandex.ru
Russian Federation, Novosibirsk; Novosibirsk

L. K. Ovchinnikova

N. N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation

Email: biochimia@yandex.ru
Russian Federation, Moscow

E. S. Gershtein

N. N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation

Email: biochimia@yandex.ru
Russian Federation, Moscow

N. E. Kushlinskii

N. N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation

Email: biochimia@yandex.ru
Russian Federation, Moscow

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2017 Springer Science+Business Media, LLC